VBL Therapeutics's Cancer Trial, And Other News: The Good, Bad And Ugly Of Biopharma [Seeking Alpha]
Sol-Gel Technologies Ltd. (SLGL)
Last sol-gel technologies ltd. earnings: 11/13 07:05 am
Check Earnings Report
US:NASDAQ Investor Relations:
nasdaq.com/markets/ipos/company/solgel-technologies-ltd-1031585-84610
Company Research
Source: Seeking Alpha
VBL Therapeutics reports progress for metastatic colorectal cancer trialVBL Therapeutics (VBLTannouncedThe Phase 2 study is designed to investigate whether priming with VB-111 and further use of nivolumab may result in inducing anti-tumor immune response in metastatic colorectal cancer. Dror Harats, M.D., Chief Executive Officer of VBL Therapeutics said, "We are pleased to see beginning of enrollment in this study, despite the challenges of COVID-19. We look forward to collaborating with the NCI on investigating VB-111 for the potential benefit of patients with colorectal cancer."The study was preceded by the company's announcement pertaining second pre-planned interim analysis of the OVAL Phase 3 potential registration study of VB-111 for treating ovarian cancer. The review was carried out by the independent Data Safety Monitoring Committee and it recommended the study to be continued as planned. For this purpose, the committee analyzed unblinded Overall Survival data pertaining the
Show less
Read more
Impact Snapshot
Event Time:
SLGL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SLGL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SLGL alerts
High impacting Sol-Gel Technologies Ltd. news events
Weekly update
A roundup of the hottest topics
SLGL
News
- Sol-Gel's Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream [Yahoo! Finance]Yahoo! Finance
- Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® CreamGlobeNewswire
- Sol-Gel Technologies Full Year 2023 Earnings: Revenues Beat Expectations, EPS In Line [Yahoo! Finance]Yahoo! Finance
- Sol-Gel Technologies GAAP EPS of -$1.01 misses by $0.31, revenue of $1.55M misses by $0.85M [Seeking Alpha]Seeking Alpha
- Sol-Gel Reports Full-Year 2023 Financial Results and Corporate DevelopmentsGlobeNewswire
SLGL
Earnings
- 11/9/23 - Beat
SLGL
Sec Filings
- 4/8/24 - Form SC
- 4/4/24 - Form 424B3
- 4/2/24 - Form EFFECT
- SLGL's page on the SEC website